


# Cancer Care Services



## Cancer Care Services

---



**Assoc. Prof. Roger Allison**  
Executive Director  
Cancer Care Services



**Adj. Assoc. Prof. Alanna Geary**  
Nursing Director  
Cancer Care Services

### Overview

Cancer Care Services at the Royal Brisbane and Women's Hospital (RBWH) is the largest cancer service in Queensland and one of the largest in Australia. The Service encompasses medical oncology, haematology and bone marrow transplant, the Queensland Haemophilia Centre, radiation oncology and nursing. It provides all treatment modalities within these streams.

2011 has been another busy and productive year for research within Cancer Care Services. We have continuing technological challenges, such as the installation of our second TomoTherapy machine, which allows us to plan and deliver complex radiotherapy treatments in a very efficient manner.

Our clinical researchers have been busy with expansion of clinical trial activity across all the divisions. Particularly pleasing is the growth in investigator-initiated research. The research grant income has increased substantially over the year and we are grateful to our donors for their ongoing financial support.

Technology continues to drive advances in oncology and as we position ourselves for 2012, we remain focussed on applying these advances to the maximum benefit of our patients.

### Key departments

- Clinical Haematology and Bone Marrow Transplant Unit
- Department of Medical Oncology
- Department of Radiation Oncology
- Queensland Haemophilia Centre

### Executive and directing staff

- **Assoc. Prof. Roger Allison**  
Executive Director, Cancer Care Services
- **Adj. Assoc. Prof. Alanna Geary**  
Nursing Director, Cancer Care Services
- **Assoc. Prof. Simon Durrant**  
Director, Clinical Haematology and Bone Marrow Transplant
- **Dr David Wyld**  
Director, Medical Oncology
- **Assoc. Prof. Graeme Dickie**  
Director, Radiation Oncology
- **Dr John Rowell**  
Director, Haematology

# Clinical Haematology and Bone Marrow Transplant Unit

## Overview

The Clinical Haematology and Bone Marrow Transplant Unit is the Clinical Haematology Referral Centre for the Central Zone, and the Bone Marrow Transplant Referral Centre for Queensland.

In addition to clinical haematology treatment, the unit provides:

- Autologous stem cell transplants
- Allogeneic stem cell and bone marrow transplants (related and unrelated)
- Clinical trials (both in-house and pharmaceutical-sponsored) for haematology and transplant patients.

The unit continues with its active research program, including a variety of local hospital and research facility studies, collaborative study group participation (such as the Australasian Leukaemia and Lymphoma Group), as well as participation in large international studies.

There is growing collaboration between departmental clinical staff and the Queensland Institute of Medical Research (QIMR), which corresponds to an improved ability to develop and participate in translational research programs.

One such collaboration is the receipt of a Senior Clinical Research Fellowship (SCRF) which is enabling the development of a national reference centre of excellence for cellular therapy of leukaemia and managing the adverse affects associated with stem cell transplant.



**Assoc. Prof. Simon Durrant**  
Director, Clinical Haematology  
and Bone Marrow Transplant

## Research staff

Name	Qualifications	Position	Interests/specialties
Assoc. Prof. Simon Durrant	MRCS, LRCP, MBBS, FRCP, FRCPath	Director, Clinical Haematology and Bone Marrow Transplant, RBWH; Assoc. Prof. Medicine, UQ	clinical haematology, bone marrow transplant
Dr Glen Kennedy	MBBS (Hons), FRACP, FRCPA	Deputy Director, Clinical Haematology and Bone Marrow Transplant, RBWH	clinical haematology, bone marrow transplant
Prof. Andrew Boyd	BMedSc, MBBS, PhD, FRACP	Consultant Haematologist, RBWH; Assistant Director, QIMR; Prof. Experimental Haematology, UQ; Senior Principal Research Fellow, QIMR	clinical haematology, bone marrow transplant
Dr Ann Gillett	MBBS, FRACP, FRCPA	Consultant Haematologist, RBWH; Clinical Haematologist	clinical haematology, bone marrow transplant
Prof. Geoff Hill	BHB, MBChB, FRACP, FRCPA, MD	Clinical Haematology and Bone Marrow Transplant Staff Specialist, RBWH	clinical haematology, bone marrow transplant, QIMR
Dr James Morton	Master of Medical Science (Epidemiology), MBBS, FRACP, FRCPA (Haematology)	Clinical Haematology and Bone Marrow Transplant Staff Specialist, RBWH	clinical haematology, bone marrow transplant
Dr Andrew Nicol	FRACP, FRCPA, PhD, MBBS	Consultant Haematologist	clinical haematology
Dr Jason Butler	MBBS, FRACP, FRCPA, MMedSci (ClinEpid) (Newcastle)	Clinical Haematology and Bone Marrow Transplant Staff Specialist, RBWH	clinical haematology, bone marrow transplant
Dr Kirk Morris	MBBS, FRACP, FRCPA	Senior Medical Officer, Clinical and Laboratory Haematology, RBWH	clinical haematology
Dr Siok Tey	MBBS, FRACP, FRCPA (Clinical Haematology and Haematopathology)	Clinical Haematology and Bone Marrow Transplant Staff Specialist, RBWH; Senior Lecturer, School of Medicine, UQ	clinical haematology, bone marrow transplant

## Research staff

Name	Qualifications	Position	Interests/specialties
Dr Ashish Misra	MBBS, FRACP, FRCPA	Staff Specialist, Haematology and Bone Marrow Transplantation, RBWH	clinical haematology, bone marrow transplant
Dr Elango Subramonia Pillai	MBBS, FRACP, FRCPA	Consultant Haematologist, Haematology and Bone Marrow Transplantation, RBWH	clinical haematology, bone marrow transplant
Dr Steven Lane	MBBS, FRACP, FRCPA, FRCP, RCPA	Clinical Haematologist, RBWH; Senior Research Officer, QIMR	clinical haematology, bone marrow transplant
Dr Cameron Curley	MBBS, FRACP, FRCPA	Staff Specialist, Haematology and Bone Marrow Transplantation, RBWH	clinical haematology, bone marrow transplant

## Publications

Jackson K, Curley C, Leach J, McLean A, Nakagaki M, Durrant S, Kennedy GA. Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD. *Bone Marrow Transplant*. 2011 Dec;46(12):1579-80. doi: 10.1038/bmt.2010.341. No abstract available.

O'Rourke K, Fairbairn DJ, Jackson KA, Morris KL, Tey SK, Kennedy GA. A novel mutation of the erythropoietin receptor gene associated with primary familial and congenital polycythaemia. *Int J Hematol*. 2011 Apr;93(4):542-4.

Janes PW, Griesshaber B, Atapattu L, Nievergall E, Hii LL, Mensinga A, Chheang C, Day BW, Boyd AW, Bastiaens PI, Jørgensen C, Pawson T, Lackmann M. J Cell Eph receptor function is modulated by heterooligomerization of A and B type Eph receptors. *Biol*. 2011 Dec 12;195(6):1033-45.

de Bock CE, Ardjmand A, Molloy TJ, Bone SM, Johnstone D, Campbell DM, Shipman KL, Yeadon TM, Holst J, Spanevello MD, Nelmes G, Catchpoole DR, Lincz LF, Boyd AW, Burns GF, Thorne RF. The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia. *Leukemia*. 2011 Nov 25. doi: 10.1038/leu.2011.319.

Goldshmit Y, Spanevello MD, Tajouri S, Li L, Rogers F, Pearse M, Galea M, Bartlett PF, Boyd AW, Turnley AM. EphA4 blockers promote axonal regeneration and functional recovery following spinal cord injury in mice. *PLoS One*. 2011;6(9):e24636.

Herath NI, Spanevello MD, Doecke JD, Smith FM, Poupponot C, Boyd AW. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. *Eur J Cancer*. 2011 Aug 16. PMID: 21852108 [PubMed - as supplied by publisher]

Day BW, Stringer BW, Spanevello MD, Charmsaz S, Jamieson PR, Ensby KS, Carter JC, Cox JM, Ellis VJ, Brown CL, Walker DG, Inglis PL, Allan S, Reynolds BA, Lickliter JD, Boyd AW. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. *Neuro Oncol*. 2011 Nov;13(11):1202-12.

Sadeqzadeh E, de Bock CE, Zhang XD, Shipman KL, Scott NM, Song C, Yeadon T, Oliveira CS, Jin B, Hersey P, Boyd AW, Burns GF, Thorne RF. Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products. *J Biol Chem*. 2011 Aug 12;286(32):28181-91.

Koyama M, Kuns RD, Olver SD, Raffelt NC, Wilson YA, Don AL, Lineburg KE, Cheong M, Robb RJ, Markey KA, Varelias A, Malissen B, Hämmerling GJ, Clouston AD, Engwerda CR, Bhat P, MacDonald KP, Hill GR. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. *Nat Med*. 2011 Nov 29;18(1):135-42. doi: 10.1038/nm.2597.

Hill GR. Vaccinating donors to improve GVL. *Blood*. 2011 Nov 24;118(22):5720-1.

Banovic T, Yanilla M, Simmons R, Robertson I, Schroder WA, Raffelt NC, Wilson YA, Hill GR, Hogan P, Nourse CB. Disseminated varicella infection caused by varicella vaccine strain in a child with low invariant natural killer T cells and diminished CD1d expression. *J Infect Dis*. 2011 Dec 15;204(12):1893-901.

Stanley AC, de Labastida Rivera F, Haque A, Sheel M, Zhou Y, Amante FH, Bunn PT, Randall LM, Pfeffer K, Scheu S, Hickey MJ, Saunders BM, Ware C, Hill GR, Tamada K, Kaye PM, Engwerda CR. Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during *Leishmania donovani* infection. *PLoS Pathog*. 2011 Oct;7(10):e1002279.

O'Sullivan BJ, Pai S, Street S, An X, MacDonald KP, Wong M, Strutton G, Gerondakis S, Steptoe RJ, de St Groth BF, Hill GR, Thomas R. Immunotherapy with costimulatory dendritic cells to control autoimmune inflammation. *J Immunol*. 2011 Oct 15;187(8):4018-30.

Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver SD, Don AL, Raffelt NC, De Weerd NA, Lineburg KE, Varelias A, Markey KA, Koyama M, Clouston AD, Hertzog PJ, Macdonald KP, Hill GR. Type I-IFNs control GVHD and GVL responses after transplantation. *Blood*. 2011 Sep 22;118(12):3399-409.

Haque A, Best SE, Ammerdorffer A, Desbarrieres L, de Oca MM, Amante FH, de Labastida Rivera F, Hertzog P, Boyle GM, Hill GR, Engwerda CR. Type I interferons suppress CD4+ T-cell-dependent parasite control during blood-stage *Plasmodium* infection. *Eur J Immunol*. 2011 Sep;41(9):2688-98. doi: 10.1002/eji.201141539.

## Publications

- McNally A, Hill GR, Sparwasser T, Thomas R, Steptoe RJ. CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis. *Proc Natl Acad Sci U S A*. 2011 May 3;108(18):7529-34.
- Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. ICBP Module 1 Working Group. *Lancet*. 2011 Jan 8;377(9760):127-38.
- Morris K, Weston H, Mollee P, Marlton P, Gill D, Kennedy G. Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone/methotrexate, cytarabine: results from an Australian population. *Leuk Lymphoma*. 2011 Jan;52(1):85-91.
- Wang F, Liu J, Robbins D, Morris K, Sit A, Liu YY, Zhao Y. Mutant p53 exhibits trivial effects on mitochondrial functions which can be reactivated by ellipticine in lymphoma cells. *Apoptosis*. 2011 Mar;16(3):301-10.
- Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. *N Engl J Med*. 2011 Nov 3;365(18):1673-83.
- Jackson K, Curley C, Leach J, McLean A, Nakagaki M, Durrant S, Kennedy GA. Alemtuzumab as salvage therapy for steroid and ATG/etanercept-refractory acute GVHD. *Bone Marrow Transplant*. 2011 Jan 24.
- O'Rourke K, Fairbairn DJ, Jackson KA, Morris KL, Tey SK, Kennedy GA. A novel mutation of the erythropoietin receptor gene associated with primary familial and congenital polycythaemia. *Int J Hematol*. 2011 Mar 25.
- Marshall KE, Morris KL, Charlton D, O'Reilly N, Lewis L, Walden H, Serpell LC. Hydrophobic, aromatic, and electrostatic interactions play a central role in amyloid fibril formation and stability. *Biochemistry*. 2011 Mar 29; 50(12); 2061-71.
- Hagop M, Katarjian, Jorge E. Cortes, Dong-Wook Kim, H. Jean Khoury, Tim H. Brummendorf, Kimmo Porkka, Giovanni Martinelli, Simon Durrant, Eric Leip, Nadine Besson, Virginia Kelly, Carlo Gambacorti-Passerini. Ski 606 – Bosutinib safety profile and management of toxicities in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors poster that was presented at the 53rd American Society of Hematology (ASH) Annual Meeting from December 10-13, 2011 in San Diego, California.
- Tawara I, Koyama M, Liu C, Toubai T, Thomas D, Evers R, Chockley P, Nieves E, Sun Y, Lowler KP, Malter C, Nishimoto N, Hill GR, Reddy P. Interleukin 6 modulates graft versus host responses after experimental allogeneic bone marrow transplantation. *Clin. Cancer Res*. 2011, 17: 77-88.
- O'Sullivan BJ, Pai S, Street S, MacDonald KPA, Wong M, Stratton G, Gerondakis S, Steptoe R, Fazekas de St Groth B, Hill GR and Thomas R. Immunotherapy with costimulatory dendritic cells to control autoimmune inflammation. *J Immunol*. 2011;187:4018-4030.

## Department of Medical Oncology



**Dr David Wyld**

Director, Medical Oncology

### Overview

The Department of Medical Oncology provides clinical services to patients at the Royal Brisbane and Women's Hospital and The Prince Charles Hospital (TPCH). It also acts as the major tertiary referral centre for the central zone, including providing outreach clinics to Rockhampton, Hervey Bay and Bundaberg. The department has an ongoing, active clinical research program.

We are currently involved in approximately 70 clinical trials. These include local hospital studies, large international studies and studies conducted as part of Australian cooperative cancer-trials groups (such as the ANZ Breast Cancer Trials Group, the ANZ Gastro-Intestinal Trials Group and the ANZ Gynaecology-Oncology Group). The worth of our trials program is acknowledged by the Queensland Cancer Fund, which provides funding for research staff on the basis of demonstrated accrual to approved, unfunded, randomised Phase II and III studies.

Several clinical staff from the unit also have broader roles within Australasian collaborative cancer trials groups, including membership of executive committees, roles as Australian Principal Investigators for some national studies, positions on individual Australia-wide trial management committees and on trial data monitoring and safety committees.

There is growing collaboration between departmental clinical staff and other institutions such as the Queensland Institute of Medical Research (QIMR) and TPCH, improving the unit's ability to develop and participate in translational research programs. Areas of specific interest include Dr Po-Ling Inglis' collaborative work in the area of neuro-oncology, Dr Brett Hughes' ongoing collaboration on pulmonary malignancies with Dr K. Fong at TPCH, and other collaborations in the areas of colorectal cancer, pancreatic cancer, head and neck malignancies, gynaecologic cancers, and neuroendocrine tumours.

The department also has ongoing research links with the Department of Nuclear Medicine at RBWH, particularly in relation to PET imaging and in the area of radioisotope therapy for specific cancers. We currently have trials in progress in these areas.

### Research staff

Name	Qualifications	Position	Interests/specialties
Dr David Wyld	MBBS (Hons), FRACP	Director, Medical Oncology	gastro-intestinal, neuroendocrine
Dr Brett Hughes	BSc (Med), MBBS (Hons), FRACP	Staff Specialist	lung, mesothelioma, head and neck, thyroid
Assoc. Prof. Nicole McCarthy	MBBS (Hons), MHSc, FRACP	Staff Specialist	breast, gynaecology
Dr Geoffrey Beadle	MBBS, FRACP, FRACR	Staff Specialist	breast cancer
Dr Matthew Burge	MB, ChB, FRACP	Staff Specialist	gastro-intestinal, Phase I studies
Dr Melissa Eastgate	MBBS, FRACP	Staff Specialist	gastro-intestinal, melanoma, head and neck cancer
Dr Michelle Nottage	MBChB, FRACP	Staff Specialist	breast, head and neck cancers
Dr Rick Abraham	MBBS, MMedSc, FRACP	Staff Specialist	lung, urology, breast cancer
Dr Po-Ling Inglis	BSc (Molecular Biology), MBBS, FRACP	Staff Specialist	breast, lung, central nervous system
Dr Jeffrey Goh	MBBS, FRACP	Staff Specialist	gynaecology, central nervous system
Dr Alison Hadley	MBBS (Hons), MMed (ClinEp), FRACP	Staff Specialist	gynaecology, breast, gastro-intestinal cancer
Dr Kathleen Houston	BMSc (Hons), MBChB, MRCP, FRACP	Staff Specialist	head and neck, pain management



## Research staff

Name	Qualifications	Position	Interests/specialties
Jenny Campbell	RN, BSc (Nursing)	Clinical Trial Coordinator	clinical trials
Annette Cubitt	RN, GradCert (Clinical Trials Management)	Clinical Trials Coordinator	clinical trials
Andrea McKenzie	EEN	Clinical Trial Coordinator	clinical trials
Amanda Earley	RN	Clinical Trial Coordinator	clinical trials
Dianna Lewis	BSc (Nursing), GradCert (Cancer Nursing)	Clinical Trial Coordinator	clinical trials
Jo-Ann Horn	RN	Clinical Trial Coordinator	clinical trials
Natasha Roberts	BN (Hons)	Clinical Trial Coordinator	clinical trials
Amy Ives	BN, AssocScN	Clinical Trial Coordinator	clinical trials
David Hickey	BAppSc	Clinical Trial Coordinator	clinical trials
Victoria Holt	BA (Hons), GradDipLibStud	Research Assistant	clinical trials
Renu Shah		Administration Officer	clinical trials

## Research grants

Investigators	Project title	Granting body	Amount awarded	Years of funding
Department of Medical Oncology	Cancer Clinical Trial Data Management Grant	Queensland Cooperative Oncology Group	\$81,600	2011
Inglis P, QIMR, QBI, RBWH	QIMR/QBI/RBWH Brain tumour and Cell Culture Bank	RBWH Private Practice Trust Fund	\$90,024	2010-2011

## Publications

Beadle G, Mengersen K, Moynihan S, Yates P. Perceptions of the ethical conduct of cancer trials by oncology nurses. *Eur J Cancer Care (Engl)*. 2011;20(5):585-92.

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Peters WP, Leonard RC, Barlow WE, Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roché H, Tokuda Y, de Vries EGE, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M and Demirel T. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomised trials. *J Clin Oncol*. 2011;29(24):3214-3223. (RBWH HREC Protocol 1996/029).

Bowman R, Relan V, Hughes B. Medical management of mesothelioma. *Aust Prescr*. 2011;34:144-147.

Chan R, Alexander A, Bransdon M, Webster J, Hughes B, Brown I, Graham T. Challenging the distal-to-proximal cannulation technique for administration of anti-cancer therapies: a prospective cohort study. *Cancer Nurs*. 2011 Nov 2.

Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Láng I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. *J Clin Oncol*. 2011;29(9):1117-1124. (RBWH HREC Protocol 2001/167).

Day BW, Stringer BW, Spanevello MD, Charmsaz S, Jamieson PR, Ensbey KS, Carter JC, Cox JM, Ellis VJ, Brown CL, Walker DG, Inglis PL, Allan S, Reynolds BA, Lickliter JD, Boyd AW. ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. *Neuro-oncol*. 2011;13(11):1202-12.

de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. *N Engl J Med*. 2011;364(21):1995-2005. (RBWH HREC Protocol 2008/028).

Joly F, Ray-Coquard I, Fabbro M, Donoghoe M, Boman K, Sugimoto A, Vaughan M, Reinhaller A, Vergote I, Ferrandina G, Dell'Anna T, Huober J, Pujade-Lauraine E. Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIg CALYPSO relapsing ovarian cancer trial. *Gynecol Oncol*. 2011;122(2):226-32. (RBWH HREC Protocol 2005/058).

## Publications

Kurtz JE, Kaminsky MC, Floquet A, Veillard AS, Kimmig R, Dorum A, Elit L, Buck M, Petru E, Reed N, Scambia G, Varsellona N, Brown C, Pujade-Lauraine E. Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCI) CALYPSO sub-study. *Ann Oncol*. 2011;22(11):2417-23. (RBWH HREC Protocol 2005/058).

Lara PN Jr, Douillard JY, Nakagawa K, von Pawel J, McKeage MJ, Albert I, Losonczy G, Reck M, Heo DS, Fan X, Fandi A, Scagliotti G. Randomised phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. *J Clin Oncol*. 2011;(22):2965-71. (RBWH HREC Protocol 2008/022).

Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J, Petru E, Reed N, GebSKI V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M. Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. *Br J Cancer*. 2011;105(3):360-5. (RBWH HREC Protocol 2005/058).

Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Hogberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, GebSKI V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. *Br J Cancer*. 2011;105(8):1144-50. (RBWH HREC Protocol 2005/058).

Mileshkin L, Hicks RJ, Hughes BGM, et al. Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine positron emission tomography imaging in patients with non-small-cell lung cancer treated with erlotinib. *Clin Cancer Res*. 2011;17:3304-3315.

Newton MJ, Hayes SC, Janda M, Webb PM, Obermair A, Eakin EG, Wyld D, Gordon LG, Beesley VL. Safety, feasibility and effects of an individualised walking intervention for women undergoing chemotherapy for ovarian cancer: A pilot study. *BMC Cancer*. 2011;11:389.

Obermair A, Mileshkin L, Bolz K, Kondalsamy-Chennakesavan S, Cheuk R, Vasey P, Wyld D, Goh J, Nicklin JL, Perrin LC, Sykes P, Janda M. Prospective, non-randomised phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. *Gynecol Oncol*. 2011;120:179-184.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stahl A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM. A phase three trial of bevacizumab in ovarian cancer. *N Engl J Med*. 2011;365:2484-96. (RBWH HREC Protocol 2007/037).

Eiermann W, Pienkowski T, Crown J, Sadeghi S, Martin M, Chan A, Saleh M, Sehdev S, Provencher L, Semiglazov V, Press M, Sauter G, Lindsay MA, Riva A, Buyse M, Drevot P, Taupin H, Mackey JR. Phase three study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. *J Clin Oncol*. 2011;29(29):3877-84. (RBWH HREC Protocol 2001/109).

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J. Adjuvant trastuzumab in HER2-positive breast cancer. *N Engl J Med*. 2011;365(14):1273-83. (RBWH HREC Protocol 2001/108).

Tran K, Bigby KJ, Hughes BGM, Lee L, Allison R. Clinicopathological report: Bilateral choroidal metastases from papillary thyroid cancer. *Asia Pac J Clin Oncol*. 2011;7(1):11-4.

Valero V, Forbes J, Pegram MD, Pienkowski T, Eiermann W, von Minckwitz G, Roche H, Martin M, Crown J, Mackay JR, Fumoleau P, Rolski J, Mrcic-Krmpotic Z, Jagiello-Gruszfeld A, Riva A, Buyse M, Taupin H, Sauter G, Press MF and Slamon DJ. Multicentre phase three randomised trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. *J Clin Oncol*. 2011;29(2):149-156. (RBWH HREC Protocol 2002/034).

Viale G, Regan MM, Dell'Orto P, Mastropasqua MG, Maiorano E, Rasmussen BB, MacGrogan G, Forbes JF, Paridaens RJ, Colleoni M, Láng I, Thürlimann B, Mouridsen H, Mauriac L, Gelber RD, Price KN, Goldhirsch A, Gusterson BA, Coates AS for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomised trial. *Ann Oncol* 2011;22(10):2201-2207. (RBWH HREC Protocol 2001/167).



## Department of Radiation Oncology

### Overview

The Department of Radiation Oncology provides radiotherapy services to a wide geographic area with treatment being delivered at the Royal Brisbane and Women's Hospital. As well as a service to The Royal Children's Hospital (RCH) and The Prince Charles Hospital (TPCH), the department provides outreach services to Rockhampton, Longreach, Hervey Bay, Maryborough, Bundaberg, Redcliffe and Caboolture Hospitals. The unit is heavily technologically driven and is fortunate to be the first Australian site to have helical tomotherapy.

It has been a productive year for cancer research in radiation oncology at RBWH. Our core clinical research activity continues in concert with the busy clinical department.

We are grateful for our donors who continue to make funds available to support our work. We are particularly proud of our success in highly competitive National Health and Medical Research Council (NHMRC) grants. Over the last few years, the trials program has progressed from largely retrospective investigator initiated trials to more translational and prospective projects.

Physics research has assumed a greater profile and we have a number of investigator-initiated projects. Our new computing cluster has dramatically improved computation time and accelerated this work. Technological progress continues and we installed our second Tomotherapy unit in late 2011. Advanced imaging remains central to these technologies. This underlines the importance of an active imaging and medical physics research program.

We look forward to further interaction with our collaborators at Queensland Institute of Medical Research (QIMR), Queensland University of Technology (QUT), The University of Queensland Centre for Clinical Research (UQCCR) and the Queensland PET Centre. We thank our collaborators and especially the many patients who have given their time to be involved in clinical trials over 2011.



**Assoc. Prof. Graeme Dickie**  
Director, Radiation Oncology

### Research staff

Name	Qualifications	Position	Interests/specialities
Assoc. Prof. Roger Allison	MBBS, MRCP, FRCR, FRANZCR, FChPM	Executive Director, Cancer Care Services	radiation oncology, paediatric
Assoc. Prof. Graeme Dickie	MBBS, MBA, FRACP, FRANZCR	Director, Radiation Oncology	radiation oncology
Dr Philip Chan	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Robyn Cheuk	MBBS (SA), DRACR	Staff Specialist	radiation oncology, paediatric
Dr Michael Fay	MBChB, FRACP, FRANZCR	Director, Research	radiation oncology, brain tumours
Dr Michelle Grogan	MBBS (Qld), FRANZCR	Staff Specialist	radiation oncology
Dr Lizbeth Kenny	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Charles Lin	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Gary Pratt	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Sue Whitaker	MBChB, DMRT, FRCR, FRANZCR	Staff Specialist	radiation oncology
Lee Tripcony	BSc	Principal Clinical Scientist (Statistics)	database, statistics
Jacqui Keller	BBus (HIM)	Manager Clinical Trials	research, clinical trials
Jennifer Edmunds	RN, BHSc	Clinical Trial Coordinator	research, clinical trials
Rebecca Pincus	RN, BN, GradCert (CDM)	Clinical Trial Coordinator	research, clinical trials
Fay Scott		Research Assistant	research, clinical trials
Greg Rattray	BAppSc (MRT), GradCertHMgt, FIR	Director, Radiation Therapy	radiation therapy
Daniel Bryant	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Kurt Burrows	BAppSc (RT)	Radiation Therapist	radiation therapy

## Research staff

Name	Qualifications	Position	Interests/specialities
Adrian Celati	BAppSc (RT)	Radiation Therapist	radiation therapy
Kevina Chroma	MHSc, MRS, GradDipHMgt	Radiation Therapist (Advanced)	radiation therapy
Stacey Cooke	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Jemma Devereaux	BAppSc (RT)	Radiation Therapist	radiation therapy
Allison Dry	Nat Dip (Diag), NatDip (RadThpy), Cert IV T&A, GradCertHlthMgmt	Senior Radiation Therapist (Education)	radiation therapy
Shayne Etherton	BAppSc (RT)	Radiation Therapist	radiation therapy
Selina Harris	BAppSc (RT)	Radiation Therapist	radiation therapy
Rob McDowall	GradCertHlthMgt, DipAppScRT	Senior Radiation Therapist (Planning)	radiation therapy
Janine Miles	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Julie-Anne Outhwaite	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Anthony Pagidas	BAppSc (RT)	Radiation Therapist	radiation therapy
Kathy Vidler	DipAppSc (RT)	Radiation Therapist	radiation therapy
Christopher Walsh	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Darren Cassidy	BSc (Hons)	A/Director Medical Physics	medical physics
Robert Fitchew	BSc (Hons), MSc	Principal Physicist	medical physics
Phil Back	BSc, MSc, PhD	Physicist (Advanced)	medical physics
Alastair Dick	BSc, MSc	A/Principal Physicist Treatment Planning and Dosimetry	medical physics
Zoe Baldwin	BSc, MSc	A/Physicist (Senior)	medical physics
Tim Markwell	BIT, BAppSc (Physics), MSc, PhD (in progress)	Physicist Oncology Treatment	medical physics
Christopher Poole	BEng, MSc, PhD (under examination)	Medical Physics (Research)	medical physics

## Supervised postgraduate students

Name	Current studies	Research topic
Outhwaite J	PhD	Head and neck immobilisation and adaptive dosimetry for variation in patient contour during treatment
Baldwin Z	Masters of Research	Commissioning of total body irradiation on oncentra masterplan
Markwell T	PhD	Mega-voltage cone-beam CT
Poole C	PhD	4D dosimetry and dose calculation

## Research grants

Investigators	Project title	Granting body	Amount awarded	Years of funding
Schofield P, Aranda S, Juraskova I, Mileskin L, Krishnasamy M, White K (Cheuk R-AI)	A nurse-led psychosocial intervention with peer support to reduce needs in women being treated with radiotherapy for gynaecological cancer: A RCT	NHMRC	\$1,133,411.80	2011-2014
Kneebone A, Williams S, Frydenberg M, Duchesne G, Fisher R, Kenny L	RAVES – Radiotherapy adjuvant versus early salvage following radical prostatectomy	NHMRC	\$775,000	2009-2013

## Research grants

Investigators	Project title	Granting body	Amount awarded	Years of funding
Rose S, Crozier S, Salvado S, Coulthard A, Thomas P, Fay M	Improving the assessment of brain tumour treatment outcome using 18F-FDOPA PET – MRI Fusion	NHMRC	\$637,125	2010-2012
Valery P, Garvey G, Fay M, Martin J, Baade P	Patterns of care, co-morbidities and quality of life in indigenous people with cancer	NHMRC	\$610,731	2011-2013
Rose S, Boyd A, Whittaker A, Thomas P, Fay M, Fisk N	The development of innovative multiplexed molecular imaging technology targeting improved diagnostic imaging of Glioblastoma Multiforme	NHMRC	\$389,925	2011 for (2012-2014)
Dickie GJ	QCOG Cancer Clinical Trial Data Manager Grant	Queensland Clinical Oncology Group	\$44,400	2011
Fay M, Rose S, Boyd A, Whitaker A, Lee E, Fisk N, Crozier S	The development of innovative molecular imaging technology targeting improved diagnostic imaging and drug delivery for glioblastoma multiforme: A proof of concept study	RBWH Foundation	\$40,000	2011
Fay M	Rotary Club, Rockhampton North	Rotary	\$20,000	2011
Fay, M Marwell, T	Low-cost high-performance Monte Carlo cluster	RBWH Private Practice Trust Fund	\$8,500	2011

## Publications

Hansen C, Kenny L, Lakhani S, Ung O, Keller J, Tripcony L, Cheuk R, Grogan M, Vargas A Vargas, Martin J. Tubular breast carcinoma: An argument against treatment de-escalation. *Journal of Medical Imaging and Radiation Oncology*. 2011;56:116–122.

Hsu C C-T, Kwan GNC, Chawla A, Mitina N, Christie D. Smoking habits of radiotherapy patients: Did the diagnosis of cancer make an impact and is there an opportunity to intervene? *Journal of Medical Imaging and Radiation Oncology*. 2011;55:526-531.

Lin C, Tripcony L, Keller J, Poulsen M, Martin J, Jackson J, Dickie G. Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. *Int J Radiat Oncol Biol Phys*. 2011;82:334-340.

Martin J, Brett R, Blyth J, Morrison S, Bryant D, Plank A, Cheuk R, Fay M, Dickie G, Yaxley J. Dosimetric effect of external beam planning preceding combined high-dose-rate brachytherapy of the prostate. *Brachytherapy* 10. 2011;474-478.

Obermair A, Mileshkin L, Bolz K, Kondalsamy-Chennakesavan S, Cheuk R, Vasey P, Wyld D, Goh J, Nicklin JL, Perrin LC, Sykes P, Janda M. Prospective, non-randomised phase two clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma. *Gynecol Oncol*. 2011 Feb;120(2):179-84.

Poole C, Trapp JV, Kenny J, Kairn T, Williams K, Taylor M, Franich R, Langton C. A hybrid radiation detector for simultaneous spatial and temporal dosimetry. *Australasian Physical and Engineering Science in Medicine*. 2011:1-6.

Proust-Lima C, Taylor JM, Secher S, Sandler H, Kestin L, Pickles T, Bae K, Allison R, Williams S. Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. *Int J Rad Oncol Biol Phys*. 2011 Jan 1;79(1):195-201.

## Queensland Haemophilia Centre



**Dr John Rowell**  
Director, Haematology

### Overview

The Queensland Haemophilia Centre is a statewide service based at the Royal Brisbane and Women's Hospital. The centre provides comprehensive care for those with haemophilia and other inherited bleeding disorders. Designated staff provide medical, nursing, physiotherapy and social work input into patient care. This includes specialised support including diagnosis, factor replacement therapy, musculo-skeletal and orthopaedic assessment and management, care and support in relation to blood-borne viruses, genetic counselling and psychosocial support.

The centre was involved in two clinical trials: A-LONG: an open-label, multicenter evaluation of the safety, pharmacokinetics and efficacy of recombinant factor VIII Fc fusion protein (rFVIII Fc) in the prevention and treatment of bleeding in previously treated subjects with severe Hemophilia; and, A and B-LONG: an open-label, multicenter evaluation of the safety, pharmacokinetics and efficacy of recombinant, long-acting coagulation factor IX Fc fusion (rFIX Fc) in the prevention and treatment of bleeding in previously treated subjects with severe Hemophilia B. Both these trials were to look at longer acting recombinant factor replacement therapy.

The Queensland Haemophilia Centre also received funding from the Haemophilia Foundation of Australia Research Fund to conduct a quality of life assessment, looking at perceived quality of life across the domains of physical, emotional and social health. This was done using the internationally recognised Haem-A-QoL questionnaire which has good reliability. The aim of the research was to ascertain a snapshot of the perceived health-related quality of life (HRQoL).

The results of this study indicated some areas in which patients with haemophilia experience the greatest impairments on their quality of life: physical health, view of self, sports and leisure, and future. Not surprisingly, those with severe haemophilia reported worse quality of life than those with moderate haemophilia.

This is the first study to use the Haem-A-QoL or any disease-specific quality of life measure within Australia. It would be helpful in the future to look toward gathering normative data for comparison with other study populations.

### Research staff

Name	Qualifications	Position	Interests/specialities
Dr John Rowell	MBBS, FRCPA, MBA	Director, Haematology, Pathology Queensland and Queensland Haemophilia Centre, CCS	haemophilia
Dr Rachel Bushing	MAPS, BPsychSc (Hons), DClinPsy	Research Assistant	research
Ms Beryl Zeissink	RN, MNurs, MSc (GenetCouns)	Clinical Nurse Consultant	haemophilia
Ms Olivia Hollingdrake	RN, GradCert (OncNursing), GradCert (Public Health)	Clinical Nurse	haemophilia
Ms Maureen Spilsbury	BSocialWk (Hons)	Advanced Social Worker	psychosocial aspects of inherited bleeding disorders
Dr Michelle Engels	MAPS, BPsych (Hons), DClinPsy	Research Assistant	research

### Research grants

Investigators	Project title	Granting body	Amount awarded	Years of funding
Rowell J, Bushing R, Spilsbury M, Engels M	Quality of life in adults with moderate and severe haemophilia: A current snapshot of the haemophilia community in Queensland, Australia	Haemophilia Foundation Australia Research Fund	\$13,731	2010-2011

## Overview

The nursing team comprises 276 nursing staff, providing quality care across the Clinical Haematology and Bone Marrow Transplant Unit, the Department of Medical Oncology, the Department of Radiation Oncology and the Queensland Haemophilia Centre.

The growing demand of cancer care has presented a challenge for the nursing profession in its workload, workforce issues, and most importantly the need to provide innovative and cost-effective nursing care.

Cancer nurses play an important and unique role in responding to the needs of people affected by cancer throughout the continuum of care, from prevention to survivorship, end-of-life care and bereavement support. The nursing research team was established in 2008 with the aim of providing an infrastructure for evidence generation and utilisation to ensure that our nursing care in Cancer Care Services is at the world class level.

Both nurse researchers are authors for the Cochrane Collaboration (a world recognised evidence-based health care organisation). They are both involved in national and international research efforts. The research team also works in partnership with Centre for Clinical Nursing, The University of Queensland (UQ), Queensland University of Technology (QUT) and Griffith University.



**Adj. Assoc. Prof. Alanna Geary**  
Nursing Director  
Cancer Care Services

## Research staff

Name	Qualifications	Position	Interests/specialities
Raymond Chan	RN, BN, MAppSc, FRCNA	Nurse Researcher	evidence-based medicine, symptom management, patient education, palliative care, supportive care
Nicole Gavin	BSc (Hons)	Nurse Researcher	central venous access devices, haematology and bone marrow transplantation nursing

## Supervised postgraduate students

Name	Current studies	Research topic
Chan R	PhD	Self-management associated with fatigue in patients with advanced cancer
Gavin N	Master of Advanced Practice	Effect of frequency of dressing changes for central venous access on central catheter infections

## Research grants

Investigators	Project title	Granting body	Amount awarded	Years of funding
Chan R (AI)	The RSVP Trial: Replacement of Intravascular device administration sets after standard versus prolonged use	NHMRC	\$1,555,000	2011-2014
Chan R	Self-management associated with fatigue in patients with advanced cancer	RBWH Foundation	\$60,000	2011
Geary A (AI)	Catheter-related bloodstream infections in adults with cancer: a prospective randomised controlled trial	Cancer Council Queensland	\$87,400	2011 for 2012-2013

---

## Publications

Chan R, Yates P, McCarthy A. The aetiology, impact and management of cancer-related fatigue in patients with advanced cancer. *Aust J Cancer Nurs.* 2011;12:2:4-11.

Chan R, Webster J. A Cochrane review on the effects of end-of-life care pathways: do they improve patient outcomes? *Aust J Cancer Nurs.* 2011;12:2:26-30.

Chan R, Webster J, Marquart L. Interventions for orienting patients and their carers to cancer care facilities (Review). *Cochrane Db Sys Rev* 2011, Issue 12. Art. No.: CD008273. DOI: 10.1002/14651858.CD008273. pub2.

Chan R, Webster J. A national rollout of an insufficiently evaluated practice: how evidence-based are our end-of-life care policies? *J Pall Med.* 2011;14:7:840.

Chan R. Cochrane review summary for cancer nursing: Drug therapy for cancer-related fatigue. *Cancer Nurs.* 2011;34:3:250-251.

Chan R. Oral Oxycodone or Oxycodone plus paracetamol for acute postoperative pain. *J Pain Manage.* 2011;4(4):439-441.

Gavin N, Webster J, Chan R, Rickard C. Effect of Frequency of dressing changes for central venous access devices on catheter-related infections (Protocol). *Cochrane Db Sys Rev* 2011. Issue 7. Art. No: CD009213. DOI:10.1002/14651858.CD009213.